Navigation Links
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
Date:8/5/2009

ain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the design and timing of further development efforts.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; acceptance of clinical trial or other data, analysis or information by the FDA in support of regulatory approval; plans and timing for commercialization of Qutenza; outcomes and interpretation of the results of clinical trials; and plans for entry into a U.S. commercialization partnership, including the timing with respect to entry into such a partnership. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpecte
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
2. NeurogesX Added to Russell 3000 Index
3. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
4. NeurogesX to Present at Needham Life Sciences Conference
5. NeurogesX Receives European Commission Approval for Qutenza(TM)
6. NeurogesX Reports First Quarter 2009 Results
7. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
8. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
9. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
10. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
11. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... that use light, rather than electricity, to move ... energy efficiency is a growing concern as chips, ... components of optical circuits light emitters, modulators, ... build. One promising light source for optical chips ... properties when deposited as a single, atom-thick layer. ...
(Date:9/19/2014)... Florida , September 19, 2014 ... medical technology, development of emerging drug systems and advanced ... Benton, Dickinson and Company (NYSE: BDX ), ... Regado Biosciences Inc. (NASDAQ: RGDO ), Sangamo ... Inc. (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: ...
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... NVAX ) today announced that the Company will ... II human clinical trial in,healthy adult subjects of Novavax,s seasonal ... 11, 2008. , The ... Officer,Dr. Rahul Singhvi and other members of senior management, including ...
... ORLANDO, Fla., Dec. 8 Building on its ... Health today,launched the Pyxis(R) MedStation(R) 4000 and an ... actionable,recommendations to help improve medication safety. , ... 4000 automated medication dispensing system,offers new features that ...
... 8 Interleukin Genetics, Inc. (Amex: ILI ), ... as Vice President, Marketing. Mr. Walker will be responsible ... reporting to the Chief Executive Officer, Lewis H. Bender. ... well as 20 years of industry-related experience. , ...
Cached Biology Technology:Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing 2Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing 3
(Date:9/19/2014)... unveiled today by researchers from several Harvard University ... both experienced and aspiring researchers with the intellectual ... robots made from soft, flexible materials. , With ... and other advances in manufacturing technology, soft robotics ... principles drawn from conventional rigid robot design, but ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2
... published in the Nov. 20 edition of Heredity ... of the evolution of separate sexes, a theory that ... These early stages are not completely understood because the ... titillating separate-sex state too long ago for scientists to ...
... CHICAGO -- The body,s immune system hates strangers. When ... it. This is the problem when people with ... islet cells from a donor pancreas produce robust amounts ... from insulin therapy. However, the immune system tries to ...
... population, and turning research into commercial enterprises, will ... million) investment announced today by the Engineering and ... (TSB) and the Biotechnology and Biological Sciences Research ... two new centres in areas where world-class scientific ...
Cached Biology News:Two from one: Pitt research maps out evolution of genders from hermaphroditic ancestors 2Researcher tricks immune system in diabetic mice 2£20 million to fight virtual crime and treat our ageing population 2£20 million to fight virtual crime and treat our ageing population 3
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
Human VASA Biotinylated Affinity Purified PAb...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
interferon-related developmental regulator 2...
Biology Products: